Lanreotide acetate CAS 127984-74-1 Treat For Acromegaly and symptomatic neuroendocrine tumors

Lanreotide acetate CAS 127984-74-1 Treat For Acromegaly and symptomatic neuroendocrine tumors

Product Name: Lanreotide Acetate
Synonyms: 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;Somatulina;LANREOTIDE ACETATE;3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;Angiopeptin acetate;10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide;Lanreotide Acetate USP/EP/BP
CAS: 127984-74-1
MF: C54H69N11O10S2
MW: 0
EINECS:
Product Categories: Amino Acids & Derivatives, Pharmaceuticals, Intermediates & Derivatives
Mol File: 127984-74-1.mol

Lanreotide acetate, an octapeptide somatostatin analog, reached its first worldwide market in France for acromegaly when surgery or radiotherapy have failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is reportedly in clinical trials for the prevention of restenosis following coronary artery angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for neuroendocrine tumors and hormone-responsive prostate cancer has also been demonstrated.

Lanreotide Acetate CAS 127984-74-1 Chemical Properties
storage temp. -20°C
form powder
color white to off-white

Function and Application of Lanreotide Acetate CAS 127984-74-1
Lanreotide acetate, like natural growth inhibitors, lanreotide is a peptide inhibitor of many endocrine, neuroendocrine, exocrine and paracrine functions. Lanreotide is more active and has a longer duration of action than natural growth inhibitors. Its inhibitory effect on growth hormone secretion is significantly more selective than that on insulin secretion, and in 2017 the FDA approved lanreotide acetate for injection for the treatment of neuroendocrine tumors.